Is it correct that ocrelizumab (Ocrevus) reduces the relapse rate by 90% and natalizumab (Tysabri) reduces it by about 80%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Relapse Rate Reduction: Ocrelizumab vs Natalizumab

The claim that ocrelizumab achieves 90% relapse reduction while natalizumab achieves 80% is not accurate based on FDA-approved data—both medications demonstrate similar relapse rate reductions of approximately 46-47% compared to interferon beta-1a, not 80-90% as absolute reductions.

Understanding the Numbers

The confusion likely stems from misinterpreting relative versus absolute reductions. Here's what the highest-quality evidence actually shows:

Ocrelizumab (Ocrevus) - FDA Label Data

In the pivotal RMS trials 1:

  • Annualized relapse rate (ARR): 0.156 (Study 1) and 0.155 (Study 2)
  • Relative reduction vs interferon beta-1a: 46-47% (p<0.0001)
  • Proportion relapse-free at 96 weeks: 82-83%

The "90%" figure you may have seen likely refers to the 94-95% reduction in MRI gadolinium-enhancing lesions 1, not clinical relapses.

Natalizumab (Tysabri) - Real-World Data

Recent high-quality real-world evidence shows 2:

  • Mean ARR on treatment: 0.04 (compared to 0.69 pre-treatment)
  • ARR reduction: Approximately 82-94% from baseline
  • Proportion with relapses: Only 8.4% during treatment (vs 88.5% pre-treatment)
  • NEDA-3 achievement: 84.0%

Another Swiss cohort demonstrated 3:

  • ARR reduction: 82% at 1 year, 69% at 2 years, 77% at 3 years (all p<0.001)

Head-to-Head Comparison

The most recent and highest-quality direct comparison found no significant difference between these medications 4:

A 2026 Danish nationwide registry study comparing ocrelizumab (n=542) versus natalizumab (n=384) in RRMS patients found:

  • Mean ARR: 0.071 for both groups (95% CI overlap completely)
  • ARR ratio: 0.996 (95% CI 0.687-1.444, p=0.983)
  • No difference in disability progression or MRI activity

However, one 2026 US claims-based study suggested natalizumab may have slightly better outcomes 5:

  • ARR: 0.20 (natalizumab) vs 0.28 (ocrelizumab), rate ratio 0.70 (p<0.001)
  • Relapse-free at 3 years: 69.9% vs 63.9% (p=0.002)

Clinical Bottom Line

Both medications are highly effective high-efficacy DMTs with:

  • Similar relapse suppression in the 80-90% relapse-free range
  • Comparable disability outcomes
  • Excellent MRI activity control

Key Differentiating Factors

Choose natalizumab when:

  • JCV antibody negative or low index (<1.5)
  • Desire for rapid onset of action
  • Preference for monthly monitoring

Choose ocrelizumab when:

  • JCV antibody positive with high index (>1.5)
  • Preference for less frequent dosing (every 6 months)
  • Primary progressive MS (only approved option)

Critical Safety Caveat

Natalizumab carries significant PML risk 6:

  • Overall PML incidence: 3.96 per 1000 patients
  • Risk stratified by JCV antibody status, prior immunosuppression, and treatment duration
  • After 25-48 months in JCV+ patients: 5/1000 (no prior immunosuppression) to 11/1000 (with prior immunosuppression)
  • With JCV index >1.5 after 49-72 months: 10.12/1000

Ocrelizumab does not carry this specific PML risk profile, making it safer for long-term use in JCV-positive patients.

Related Questions

How should ocrelizumab (Ocrevus) be administered, monitored, and what are its contraindications for patients with relapsing‑remitting or primary progressive multiple sclerosis?
Can a patient with multiple sclerosis who had a myocardial infarction within the past three months safely start Ocrevus (ocrelizumab)?
What are the management recommendations for patients developing leukocytosis while being treated with Ocrevus (ocrelizumab)?
Why are Mavenclad (cladribine) or hematopoietic stem cell transplant considered next options for a patient with multiple sclerosis (MS) showing radiographic evidence of disease progression while on Ocrevus (ocrelizumab)?
What are the high‑efficacy disease‑modifying therapies for a patient with highly active relapsing‑remitting multiple sclerosis?
What is the sensitivity of a throat swab for detecting Group A Streptococcus in a 5‑year‑old child?
What are the indications, dosing regimens, monitoring requirements, and escalation criteria for interferon‑beta therapy in relapsing‑remitting multiple sclerosis?
What is the appropriate dosage and duration of therapy for a 5% lidocaine patch used for pain management?
What antibiotic regimen should be prescribed for a female patient who is allergic to Bactrim, nitrofurantoin, and futon toxin but not allergic to cephalexin (Keflex)?
Can I use vitamin C 1000 mg, zinc 15 mg, vitamin D, the Wellman Conception multivitamin, vitamin E 400 mg, and Speman tablets to improve oligospermia and teratozoospermia?
Can lercanidipine be used for chronic coronary syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.